Joining Forces with Zai Lab: What is the Remaining Market Potential for Opdivo in China?
Bristol Myers Squibb (BMS) recently announced the transfer of sales rights for one of its core products, the PD-1 monoclonal antibody Opdivo (nivolumab), in select provinces within China to the local biotechnology firm Zai Lab Limited (ZLAB).
March 6, 2024
by Yefenghong
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors
Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines...
December 13, 2021
by prnasia
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carci
Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono).
August 26, 2021
by firstwordpharma
US clears BMS' Opdivo as first adjuvant therapy for bladder cancer
Bristol Myers Squibb said Friday that the FDA has expanded Opdivo's (nivolumab) urothelial carcinoma (UC) indication to include adjuvant use in high-risk patients, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
August 23, 2021
by firstwordpharma
EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease ...
August 3, 2021
by pharmatimes
BMS 2Q Revenues up 16%
Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.
August 2, 2021
by contractpharma
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer
The European Commission (EC) has approved Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy immunotherapy regimen for the treatment of certain metastatic colorectal patients (mCRC), the company announced 29th.
July 1, 2021
by pharmatimes
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
Bristol Myers Squibb’s (BMS) immunotherapy combination Opdivo plus Yervoy has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of certain advanced bowel cancer patients.
June 16, 2021
by pharmatimes
Opdivo combos show OS benefit in advanced oesophageal cancer
Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients.
June 10, 2021
by pharmatimes
EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
June 4, 2021
by americanpharmaceuticalreview
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer
Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for ...
May 26, 2021
by pharmatimes
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
May 25, 2021
by pharmatimes